Atossa Therapeutics, Inc. (ATOS)

NasdaqCM • Currently down 0.01 (-0.40%) in today's trading session

1 member of Congress has disclosed 3 trades in Atossa Therapeutics, Inc. (ATOS) via STOCK Act filings. The most recent disclosure was a purchase by Roger Marshall on 25 October 2017. Aggregate disclosed activity totals roughly $24K in purchases (midpoint estimates from bracketed disclosure amounts).

Atossa Therapeutics, Inc. is currently trading at $2.52, positioned at 5% of its 52-week range ($1.70 – $19.35).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Automatically with eToro

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$2.52
24h Change
-0.01 (-0.40%)
52 Week Range
$1.70–$19.35
View on NASDAQ

Atossa Therapeutics, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for ATOS

Select to highlight on chart
3 transactions
Compliance: 0%
Roger Marshall25 Oct 201710 Aug 2018PurchaseStock$1,001 - $15,000N/A
Roger Marshall25 Oct 20176 Aug 2018PurchaseStock$1,001 - $15,000N/A
Roger Marshall25 Oct 201713 Aug 2020PurchaseStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$25.14M

Volume

28.03K

Beta

1.27

P/E Ratio

-0.59

Fundamentals

EPS

$-4.30

Div. Yield

-

Open

$2.51

Day Range

$2.46 – $2.52

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Steven C. Quay
IPO Date
2012-11-08
Website
www.atossatherapeutics.com

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions,...

Earnings

Next Report

Q3 2026

11 Nov

EPS Est.

$-0.92

Rev. Est.

-

Days Until

64

Recent Quarters

Q2 20267 Aug
EPS$-0.95
Beat 6.9%
Q1 20268 May
EPS$-1.11
Beat 9.0%
Q4 202525 Mar
EPS$-1.19
Miss 4.6%
Q3 202512 Nov
EPS$-1.05
Miss 7.7%
Q2 202512 Aug
EPS$-1.05
Miss 16.7%
Q1 202513 May
EPS$-0.75
Miss 1150.0%
Q4 202425 Mar
EPS$-0.75
Beat 16.7%
Q3 202412 Nov
EPS$-0.75
Miss 1150.0%
Q2 202412 Aug
EPS$-0.75
Miss 1150.0%
Q1 202413 May
EPS$-0.75
Miss 971.4%
Q1 20241 Apr
EPS$-0.90
Miss 20.0%
Q3 202313 Nov
EPS$-0.05
Beat 28.6%
Q2 202314 Aug
EPS$-0.08
Miss 33.3%
Q1 202315 May
EPS$-0.75
Miss 1150.0%
Q4 202222 Mar
EPS$-0.90
Miss 1284.6%
Q3 20227 Nov
EPS$-0.06
Miss 9.1%
Q2 20228 Aug
EPS$-0.75
Miss 1400.0%
Q1 20229 May
EPS$-0.60
Miss 1100.0%
Q4 202128 Feb
EPS$-0.60
Miss 1233.3%
Q3 202115 Nov
EPS$-0.60
Miss 1400.0%
Q2 202113 Aug
EPS$-0.90
Miss 2150.0%
Q1 202114 May
EPS$-0.60
Miss 1100.0%
Q4 202031 Mar
EPS$-13.34
Q3 202013 Nov
EPS$-5.10
Miss 1400.0%
Q2 202013 Aug
EPS$-6.45
Miss 2203.6%
Q1 202013 May
EPS$-4.80
Miss 1130.8%
Q4 201926 Mar
EPS$-3.90
Miss 1081.8%
Q3 201913 Nov
EPS$-5.40
Miss 938.5%
Q2 201913 Aug
EPS$-11.99
Miss 2397.9%
Q1 201913 May
EPS$-9.30
Q4 201828 Mar
EPS$-0.50
Beat 19.4%
Q3 201813 Nov
EPS$-9.60
Miss 33.3%
Q2 201813 Aug
EPS$-43.48
Miss 292.1%
Q1 201814 May
EPS$-10.64
Miss 1137.2%
Q4 20178 Mar
EPS$-2.04
Miss 142.9%
Q3 201714 Nov
EPS$-30.60
Beat 41.4%
Q2 201714 Aug
EPS$-115.19
Miss 45.5%
Q1 201711 May
EPS$-80.99
Q4 201616 Mar
EPS$-138.59
Q3 201614 Nov
EPS$12.60
Beat 105.5%
Q2 201612 Aug
EPS$-134.92
Beat 28.6%
Q1 20165 May
EPS$-188.89
Q4 201530 Mar
EPS$-4.25
Q3 201512 Nov
EPS$-4.05
Miss 36.4%
Q2 20156 Aug
EPS$-2.97
Beat 8.3%
Q1 201513 May
EPS$-3.51
Miss 18.2%
Q4 201430 Mar
EPS$-6.48
Q3 201412 Nov
EPS$-3.51
Q2 201412 Aug
EPS$-6.21
Q1 201414 May
EPS$-2.70
Miss 1262.8%
Q4 201327 Mar
EPS$-4.05
Beat 25.0%
Q3 201312 Nov
EPS$-5.94
Miss 46.7%
Q2 201314 Aug
EPS$-4.59
Miss 21.4%
Q1 201315 May
EPS$-25.20
Miss 40.0%
Q4 201228 Mar
EPS$-19.80
Beat 0.0%
Q3 201221 Dec
EPS$-2.39
Q1 201230 Jun
EPS$-280.15
Q4 201131 Mar
EPS$-254.96
Q3 201131 Dec
EPS$-289.13
Q2 201130 Sept
EPS$-305.27
Q1 201130 Jun
EPS$-260.43
Q4 201031 Mar
EPS$-55.26
Q3 201031 Dec
EPS$-82.17
Q2 201030 Sept
EPS$-115.72
Q1 201030 Jun
EPS$-47.28
Q2 200930 Sept
EPS$-22.21

3 politicians traded within 30 days

No dividend data available for this stock.

Stock Splits

Split History

2 Feb 2026Reverse Split
Ratio1:15
20 Apr 2018Reverse Split
Ratio1:12
26 Aug 2016Reverse Split
Ratio1:15

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about ATOS

Which members of Congress have traded ATOS?
1 member of Congress has disclosed 3 trade in Atossa Therapeutics, Inc. (ATOS) under the STOCK Act: Roger Marshall.
When was ATOS most recently disclosed by Congress?
The most recent ATOS disclosure was a purchase by Roger Marshall on 25 October 2017.
What is the total disclosed congressional trading volume for ATOS?
Members of Congress have disclosed approximately $24K in ATOS purchases (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in ATOS?
This ATOS page updates as soon as new STOCK Act disclosures are filed for Atossa Therapeutics, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.